"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Completion of Enrollment of the First Subject in the Phase III Clinical Trial of Yizekang (Izalontamab Brengitecan, BL-B01D1/iza-bren) for Maintenance Therapy After Concurrent Chemoradiotherapy in Unresectable EGFR-Mutant Non-Small Cell Lung Cancer

Announcement on Voluntary Disclosure of the Completion of Enrollment of the First Subject in the Phase III Clinical Trial of Yizekang (Izalontamab Brengitecan, BL-B01D1/iza-bren) for Maintenance Therapy After Concurrent Chemoradiotherapy in Unresectable EGFR-Mutant Non-Small Cell Lung Cancer

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment